BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, Gibbs CS, Parvaz P, Werle B, Trépo C. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol. 2003;39:1085-1089. [PMID: 14642631 DOI: 10.1016/j.jhep.2003.09.022] [Cited by in Crossref: 226] [Cited by in F6Publishing: 213] [Article Influence: 12.6] [Reference Citation Analysis]
Number Citing Articles
1 Kwon HC, Cheong JY, Cho SW, Choi JM, Hong SP, Kim SO, Yoo WD. Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy. J Gastroenterol Hepatol 2009;24:49-54. [PMID: 19196395 DOI: 10.1111/j.1440-1746.2008.05570.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
2 Osiowy C, Villeneuve JP, Heathcote EJ, Giles E, Borlang J. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol. 2006;44:1994-1997. [PMID: 16757589 DOI: 10.1128/jcm.02477-05] [Cited by in Crossref: 52] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
3 Fournier C, Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin Liver Dis. 2007;11:869-892, ix. [PMID: 17981233 DOI: 10.1016/j.cld.2007.08.013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
4 Delaney WE 4th, Yang H, Miller MD, Gibbs CS, Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 2004;48:3702-10. [PMID: 15388423 DOI: 10.1128/AAC.48.10.3702-3710.2004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
5 Coffin CS, Lee SS. Treatment of HBeAg-positive patients with nucleos/tide analogues. Liver International 2009;29:116-24. [DOI: 10.1111/j.1478-3231.2008.01935.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
6 Lee YB, Lee JH, Choi WM, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Yu SJ, Kim YJ, Yoon JH, Kim CY, Lee HS. Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. Antimicrob Agents Chemother 2013;57:6325-32. [PMID: 24100506 DOI: 10.1128/AAC.01742-13] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
7 Chotiyaputta W, Lok ASF. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009;6:453-62. [DOI: 10.1038/nrgastro.2009.107] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 8.4] [Reference Citation Analysis]
8 Deng L, Tang H. Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites. Hepatol Res. 2011;41:1017-1024. [PMID: 21917087 DOI: 10.1111/j.1872-034x.2011.00873.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
9 Beckebaum S, Cicinnati VR, Gerken G, Broelsch CE. Management of chronic hepatitis B in the liver transplant setting. Transplantation Reviews 2004;18:171-82. [DOI: 10.1016/j.trre.2004.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
10 Si Ahmed SN, Zoulim F. Pathobiology of HBV mutants and clinical impact for treatment monitoring. Expert Review of Anti-infective Therapy 2014;7:309-20. [DOI: 10.1586/eri.09.10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
11 Shaw T, Locarnini S. Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther. 2004;2:853-871. [PMID: 15566330 DOI: 10.1586/14789072.2.6.853] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
12 Lu JJ, Liu K, Ma YJ, Wang J, Chen EQ, Tang H. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. J Viral Hepat. 2013;20 Suppl 1:40-45. [PMID: 23458523 DOI: 10.1111/jvh.12062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
13 Zhang Y, He S, Li Q, Guo J. Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy. Virus Research 2013;177:156-62. [DOI: 10.1016/j.virusres.2013.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
14 Chang UI, Lee YC, Wie SH, Jang JW, Bae SH, Choi JY, Yang JM, Yoon SK, Sun HS. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy. J Med Virol 2007;79:902-10. [PMID: 17516533 DOI: 10.1002/jmv.20819] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
15 Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol. 2006;44:422-431. [PMID: 16364492 DOI: 10.1016/j.jhep.2005.11.036] [Cited by in Crossref: 119] [Cited by in F6Publishing: 111] [Article Influence: 7.0] [Reference Citation Analysis]
16 Michailidis E, Kirby KA, Hachiya A, Yoo W, Hong SP, Kim SO, Folk WR, Sarafianos SG. Antiviral therapies: focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol. 2012;44:1060-1071. [PMID: 22531713 DOI: 10.1016/j.biocel.2012.04.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
17 Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective. Liver Transpl 2005;11:716-32. [DOI: 10.1002/lt.20492] [Cited by in Crossref: 127] [Cited by in F6Publishing: 104] [Article Influence: 7.5] [Reference Citation Analysis]
18 Zoulim F. [Current data on the treatment of chronic hepatitis B]. Presse Med 2008;37:287-93. [PMID: 18042341 DOI: 10.1016/j.lpm.2007.06.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Lok ASF. Liver transplantation for patients with lamivudine-resistant HBV: What is the optimal prophylactic strategy? Liver Transpl 2005;11:490-3. [DOI: 10.1002/lt.20409] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
20 Echevarría JM, Avellón A. Hepatitis B virus genetic diversity. J Med Virol 2006;78:S36-42. [DOI: 10.1002/jmv.20605] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 5.8] [Reference Citation Analysis]
21 Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007;45:307-313. [PMID: 17256746 DOI: 10.1002/hep.21534] [Cited by in Crossref: 243] [Cited by in F6Publishing: 220] [Article Influence: 16.2] [Reference Citation Analysis]
22 Zoulim F. Emerging drugs for hepatitis B. Expert Opin Emerg Drugs 2007;12:199-217. [PMID: 17604497 DOI: 10.1517/14728214.12.2.199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
23 Ismail AM, Sharma OP, Kumar MS, Kannangai R, Abraham P. Impact of rtI233V mutation in hepatitis B virus polymerase protein and adefovir efficacy: Homology modeling and molecular docking studies. Bioinformation. 2013;9:121-125. [PMID: 23423477 DOI: 10.6026/97320630009121] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
24 Hu JL, Cui J, Deng XY, Zhang WL, Li QL, Guo JJ, Zeng AZ, Huang AL. A new strategy for constructing in vitro replication-competent 1.3 copies of hepatitis B virus genome. J Virol Methods 2009;161:63-9. [PMID: 19481116 DOI: 10.1016/j.jviromet.2009.05.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
25 Larrat S, Hilleret MN, Germi R, Lupo J, Nicod S, Zarski JP, Seigneurin JM, Morand P. Sustained virological and biochemical responses to lamivudine and adefovir dipivoxil combination in a chronic hepatitis B infection despite mutations conferring resistance to both drugs. Comp Hepatol 2008;7:3. [PMID: 18336716 DOI: 10.1186/1476-5926-7-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
26 Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056-1075. [PMID: 17393513 DOI: 10.1002/hep.21627] [Cited by in Crossref: 407] [Cited by in F6Publishing: 371] [Article Influence: 27.1] [Reference Citation Analysis]
27 Ghany M, Liang TJ. Drug Targets and Molecular Mechanisms of Drug Resistance in Chronic Hepatitis B. Gastroenterology 2007;132:1574-85. [DOI: 10.1053/j.gastro.2007.02.039] [Cited by in Crossref: 122] [Cited by in F6Publishing: 108] [Article Influence: 8.1] [Reference Citation Analysis]
28 Nguyen NH, Trinh HN, Nguyen TT, Do ST, Tran P, Nguyen HA, Nguyen KK, Garcia RT, Lutchman GA, Nguyen MH. Safety and efficacy of entecavir in adefovir-experienced patients. J Gastroenterol Hepatol. 2015;30:43-50. [PMID: 25168842 DOI: 10.1111/jgh.12728] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
29 Cavallone D, Moriconi F, Colombatto P, Oliveri F, Bonino F, Brunetto MR. Optimization of in vitro HBV replication and HBsAg production in HuH7 cell line. Journal of Virological Methods 2013;189:110-7. [DOI: 10.1016/j.jviromet.2013.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
30 Mutimer D. Review article: hepatitis B and liver transplantation. Aliment Pharmacol Ther 2006;23:1031-41. [DOI: 10.1111/j.1365-2036.2006.02855.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
31 Yadav V, Chu CK. Molecular mechanisms of adefovir sensitivity and resistance in HBV polymerase mutants: a molecular dynamics study. Bioorg Med Chem Lett. 2004;14:4313-4317. [PMID: 15261293 DOI: 10.1016/j.bmcl.2004.05.075] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
32 Zoulim F. Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? Antivir Chem Chemother. 2004;15:299-305. [PMID: 15646643 DOI: 10.1177/095632020401500602] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
33 Delaney WE. Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. J Antimicrob Chemother. 2007;59:827-832. [PMID: 17332007 DOI: 10.1093/jac/dkl551] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
34 Beck IA, Payant R, Ngo-Giang-Huong N, Khamduang W, Laomanit L, Jourdain G, Frenkel LM. Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus. J Virol Methods 2016;233:51-5. [PMID: 27025356 DOI: 10.1016/j.jviromet.2016.03.014] [Reference Citation Analysis]
35 Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C;  Hepatitis B Virus Drug Resistance Working Group. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46:254-265. [PMID: 17596850 DOI: 10.1002/hep.21698] [Cited by in Crossref: 328] [Cited by in F6Publishing: 306] [Article Influence: 21.9] [Reference Citation Analysis]
36 Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, Chung YH, Lee YS, Yoo W, Kim SO. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006;43:1385-1391. [PMID: 16729316 DOI: 10.1002/hep.21189] [Cited by in Crossref: 239] [Cited by in F6Publishing: 214] [Article Influence: 14.9] [Reference Citation Analysis]
37 Langley DR, Walsh AW, Baldick CJ, Eggers BJ, Rose RE, Levine SM, Kapur AJ, Colonno RJ, Tenney DJ. Inhibition of hepatitis B virus polymerase by entecavir. J Virol. 2007;81:3992-4001. [PMID: 17267485 DOI: 10.1128/jvi.02395-06] [Cited by in Crossref: 125] [Cited by in F6Publishing: 60] [Article Influence: 8.3] [Reference Citation Analysis]
38 Lacombe K, Ollivet A, Gozlan J, Durantel S, Tran N, Girard P, Zoulim F. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV–hepatitis B virus-co-infected patient. AIDS 2006;20:2229-31. [DOI: 10.1097/01.aids.0000252061.35422.84] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
39 Ko SY, Kim BK, Kwon SY, Kim KH, Kim JH, Choe WH, Lee CH. Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment. World J Gastroenterol 2012; 18(44): 6437-6446 [PMID: 23197889 DOI: 10.3748/wjg.v18.i44.6437] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
40 Lim YS, Yoo BC, Byun KS, Kwon SY, Kim YJ, An J, Lee HC, Lee YS. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut. 2016;65:1042-1051. [PMID: 25800784 DOI: 10.1136/gutjnl-2014-308435] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 8.9] [Reference Citation Analysis]
41 Manolakopoulos S, Bethanis S, Koutsounas S, Goulis J, Vlachogiannakos J, Christias E, Saveriadis A, Pavlidis C, Triantos C, Christidou A, Papatheodoridis G, Karamanolis D, Tzourmakliotis D. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment Pharmacol Ther 2008;27:266-73. [PMID: 17988233 DOI: 10.1111/j.1365-2036.2007.03567.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
42 Lee YB, Lee JH, Choi WM, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Yu SJ, Kim YJ. Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. Antimicrob Agents Chemother. 2013;57:6325-6332. [PMID: 24100506 DOI: 10.1128/aac.01742-13aac.01742-13] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Lok AS. How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting. Liver Transpl. 2008;14 Suppl 2:S8-S14. [PMID: 18825720 DOI: 10.1002/lt.21616] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
44 Laryea MA, Watt KD. Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation. Liver Transpl. 2012;18:514-523. [PMID: 22315212 DOI: 10.1002/lt.23408] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
45 Barreiro P, Martín-Carbonero L, García-Samaniego J. [Hepatitis B in patients with HIV infection]. Enferm Infecc Microbiol Clin 2008;26 Suppl 7:71-9. [PMID: 19100234 DOI: 10.1016/s0213-005x(08)76522-4] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
46 Lucifora J, Durantel D, Belloni L, Barraud L, Villet S, Vincent IE, Margeridon-Thermet S, Hantz O, Kay A, Levrero M, Zoulim F. Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector. J Gen Virol. 2008;89:1819-1828. [PMID: 18632952 DOI: 10.1099/vir.0.83659-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
47 Cuestas ML, Mathet VL, Oubiña JR, Sosnik A. Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection. Pharm Res 2010;27:1184-202. [PMID: 20333454 DOI: 10.1007/s11095-010-0112-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
48 Kawamura E, Habu D, Hayashi T, Oe A, Kotani J, Ishizu H, Torii K, Kawabe J, Fukushima W, Tanaka T, Nishiguchi S, Shiomi S. Natural history of major complications in hepatitis C virus-related cirrhosis evaluated by per-rectal portal scintigraphy. World J Gastroenterol 2005; 11(25): 3882-3886 [PMID: 15991287 DOI: 10.3748/wjg.v11.i25.3882] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
49 Ducancelle A, Pivert A, Bertrais S, Boursier J, Balan V, Veillon P, le Guillou-Guillemette H, Thibault V, Castelain S, Roquebert B, Coste-Burel M, Mackiewicz V, Schvoerer E, Larrat S, Maylin S, Alain S, Loustaud-Ratti V, Gordien E, Gozlan J, Brodard V, Chevaliez S, Calès P, Lunel-Fabiani F. Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity. J Gastroenterol Hepatol 2016;31:1750-6. [PMID: 26992056 DOI: 10.1111/jgh.13338] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
50 Sáez-López A, Agüero-Balbín J. [Hepatitis B and C virus antiviral resistance]. Enferm Infecc Microbiol Clin 2006;24:576-84. [PMID: 17125678 DOI: 10.1157/13093879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Durantel D, Brunelle MN, Gros E, Carrouée-Durantel S, Pichoud C, Villet S, Trepo C, Zoulim F. Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. J Clin Virol. 2005;34 Suppl 1:S34-S43. [PMID: 16461221 DOI: 10.1016/s1386-6532(05)80008-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
52 Zoutendijk R, Reijnders JG, Brown A, Zoulim F, Mutimer D, Deterding K, Petersen J, Hofmann WP, Buti M, Santantonio T. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology. 2011;54:443-451. [PMID: 21563196 DOI: 10.1002/hep.24406] [Cited by in Crossref: 125] [Cited by in F6Publishing: 120] [Article Influence: 11.4] [Reference Citation Analysis]
53 Reijnders JG, Janssen HL. Potency of tenofovir in chronic hepatitis B: mono or combination therapy? J Hepatol. 2008;48:383-386. [PMID: 18191272 DOI: 10.1016/j.jhep.2007.12.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
54 Malagnino V, Fofana DB, Lacombe K, Gozlan J. Occult Hepatitis B Virus Infection: An Old Entity With Novel Clinical Involvements. Open Forum Infect Dis 2018;5:ofy227. [PMID: 30324127 DOI: 10.1093/ofid/ofy227] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
55 Sun M, Tan G, Song J, Wang J, Wu X. Profile of HBV polymerase gene mutations during entecavir treatment in patients with chronic hepatitis B. Clin Res Hepatol Gastroenterol 2016;40:590-6. [PMID: 27016894 DOI: 10.1016/j.clinre.2016.02.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
56 Wang Y, Liu S, Chen YU, Zheng S, Zhou LI, Lu F, Duan Z. Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. Exp Ther Med. 2016;11:2293-2299. [PMID: 27313669 DOI: 10.3892/etm.2016.3230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
57 Moriconi F, Colombatto P, Coco B, Ciccorossi P, Oliveri F, Flichman D, Maina AM, Sacco R, Bonino F, Brunetto MR. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. J Antimicrob Chemother. 2007;60:341-349. [PMID: 17567633 DOI: 10.1093/jac/dkm187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
58 Villet S, Pichoud C, Villeneuve JP, Trépo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology. 2006;131:1253-1261. [PMID: 17030194 DOI: 10.1053/j.gastro.2006.08.013] [Cited by in Crossref: 125] [Cited by in F6Publishing: 120] [Article Influence: 7.8] [Reference Citation Analysis]
59 Zeng T, Xu H, Liu JY, Lei Y, Zhong S, Zhou Z. Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis. J Clin Pharmacol 2014;54:959-67. [PMID: 24964070 DOI: 10.1002/jcph.351] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
60 Brunetto MR. Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance. Journal of Hepatology 2007;46:756-8. [DOI: 10.1016/j.jhep.2007.02.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
61 Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bömmel F, Hansen BE, Wedemeyer H, Janssen HL. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol. 2010;52:493-500. [PMID: 20185191 DOI: 10.1016/j.jhep.2010.01.012] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 6.8] [Reference Citation Analysis]
62 Nath DS, Kalis A, Nelson S, Payne WD, Lake JR, Humar A. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant. 2006;20:206-210. [PMID: 16640528 DOI: 10.1111/j.1399-0012.2005.00467.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
63 Gallego A, Sheldon J, García-Samaniego J, Margall N, Romero M, Hornillos P, Soriano V, Enrĺquez J. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hepat 2008;15:392-8. [PMID: 18221300 DOI: 10.1111/j.1365-2893.2007.00966.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
64 Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44:675-684. [PMID: 16941693 DOI: 10.1002/hep.21282] [Cited by in Crossref: 314] [Cited by in F6Publishing: 308] [Article Influence: 19.6] [Reference Citation Analysis]
65 Soriano V, Nuñez M, Sheldon J, Ramos B, Garcia-Samaniego J, Martín-Carbonero L, Maida I, Gonzalez-Lahoz J. Complications in treating chronic hepatitis B in patients with HIV. Expert Opin Pharmacother 2005;6:2831-42. [PMID: 16318434 DOI: 10.1517/14656566.6.16.2831] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
66 Fung SK, Lok AS. Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B. Nat Clin Pract Gastroenterol Hepatol. 2004;1:90-97. [PMID: 16265070 DOI: 10.1038/ncpgasthep0056] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
67 Marlet J, Lier C, Roch E, Moreau A, Combe B, Handala L, Lefeuvre S, Maugey M, Elkrief L, d'Alteroche L, Potier P, Brand D, Gaudy-Graffin C. Evolution and phenotypic characterization of whole HBV genome in compliant patients experiencing unexplained entecavir treatment failure. Antiviral Res 2021;192:105106. [PMID: 34214504 DOI: 10.1016/j.antiviral.2021.105106] [Reference Citation Analysis]
68 Roger S, Lefeuvre C, Grison M, Ducancelle A, Lunel-Fabiani F, Pivert A, Le Guillou-Guillemette H. Evaluation of the Aptima™ HBV Quant Dx assay for semi-quantitative HBV viral load from dried blood spots. J Clin Virol 2020;129:104524. [PMID: 32629186 DOI: 10.1016/j.jcv.2020.104524] [Reference Citation Analysis]
69 Dai CY, Chuang WL, Hsieh MY, Lee LP, Huang JF, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antiviral Res. 2007;75:146-151. [PMID: 17400303 DOI: 10.1016/j.antiviral.2007.02.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
70 Villet S, Billioud G, Pichoud C, Lucifora J, Hantz O, Sureau C, Dény P, Zoulim F. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology. 2009;136:168-176.e2. [PMID: 18996386 DOI: 10.1053/j.gastro.2008.09.068] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.4] [Reference Citation Analysis]
71 Roche B, Samuel D. [Prevention and treatment of hepatitis B virus infection after liver transplantation]. Gastroenterol Clin Biol 2005;29:393-404. [PMID: 15864201 DOI: 10.1016/s0399-8320(05)80787-0] [Reference Citation Analysis]
72 Brunelle MN, Lucifora J, Neyts J, Villet S, Holy A, Trepo C, Zoulim F. In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. Antimicrob Agents Chemother. 2007;51:2240-2243. [PMID: 17371827 DOI: 10.1128/aac.01440-06] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
73 Schreibman IR, Schiff ER. Entecavir: a new treatment for chronic hepatitis B infection. Future Virology 2006;1:541-52. [DOI: 10.2217/17460794.1.5.541] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
74 Marlet J, Lier C, Roch E, Maugey M, Moreau A, Combe B, Lefeuvre S, d'Alteroche L, Barbereau D, Causse X, Bastides F, Bachelier MN, Brand D, Gaudy-Graffin C. Revisiting HBV resistance to entecavir with a phenotypic approach. Antiviral Res 2020;181:104869. [PMID: 32735901 DOI: 10.1016/j.antiviral.2020.104869] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
75 Bottero J, Boyd A, Gozlan J, Lemoine M, Carrat F, Collignon A, Boo N, Dhotte P, Varsat B, Muller G. Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France. J Hepatol. 2013;58:473-478. [PMID: 23183527 DOI: 10.1016/j.jhep.2012.11.016] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
76 Moses SE, Lim Z, Zuckerman MA. Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther. 2011;9:891-899. [PMID: 21973301 DOI: 10.1586/eri.11.105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
77 Luo YY, Tao Y, Cai XF, Zhang WL, Long QX, Guo H, Huang AL, Hu JL. A novel method for nucleos(t)ide analogues susceptibility assay of hepatitis B virus by viral polymerase transcomplementation. Antiviral Res 2016;126:99-107. [PMID: 26738784 DOI: 10.1016/j.antiviral.2015.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
78 Ratziu V, Thibault V, Benhamou Y, Poynard T. Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant. Comp Hepatol. 2006;5:1. [PMID: 16405720 DOI: 10.1186/1476-5926-5-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
79 Fournier C, Zoulim F. [Combination therapy in chronic hepatitis B]. Gastroenterol Clin Biol 2008;32:S42-9. [PMID: 18662609 DOI: 10.1016/S0399-8320(08)73264-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
80 Zoulim F, Buti M, Lok AS. Antiviral-resistant hepatitis B virus: can we prevent this monster from growing? J Viral Hepat. 2007;14 Suppl 1:29-36. [PMID: 17958640 DOI: 10.1111/j.1365-2893.2007.00915.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
81 Jiang Y, Ma Z, Xin G, Yan H, Li W, Xu H, Hao C, Niu J, Zhao P. Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm. 2010;2010:143026. [PMID: 21127728 DOI: 10.1155/2010/143026] [Cited by in Crossref: 34] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
82 Kim JH, Park YK, Park ES, Kim KH. Molecular diagnosis and treatment of drug-resistant hepatitis B virus. World J Gastroenterol 2014; 20(19): 5708-5720 [PMID: 24914332 DOI: 10.3748/wjg.v20.i19.5708] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
83 Roche B, Samuel D. Transplantation and prevention of reinfection. Curr hepatitis rep 2004;3:67-75. [DOI: 10.1007/s11901-004-0012-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
84 Hardikar W, Schwarz KB. Treatment options for chronic hepatitis B and C infection in children. Expert Review of Anti-infective Therapy 2014;4:583-91. [DOI: 10.1586/14787210.4.4.583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
85 Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol. 2010;53:449-454. [PMID: 20646776 DOI: 10.1016/j.jhep.2010.03.020] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
86 Carosi G, Rizzetto M. Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig Liver Dis. 2008;40:603-617. [PMID: 18499540 DOI: 10.1016/j.dld.2008.03.011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
87 Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol. 2008;48 Suppl 1:S2-S19. [PMID: 18304680 DOI: 10.1016/j.jhep.2008.01.011] [Cited by in Crossref: 107] [Cited by in F6Publishing: 106] [Article Influence: 7.6] [Reference Citation Analysis]
88 Mateos ML, Tato M, Moreira V. [Lamivudine and adefovir resistance in a patient with HBeAg negative chronic hepatitis B]. Gastroenterol Hepatol 2006;29:71-3. [PMID: 16448607 DOI: 10.1157/13083902] [Reference Citation Analysis]
89 Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004;10:S74-85. [DOI: 10.1002/lt.20258] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 3.5] [Reference Citation Analysis]
90 Boyd A, Gozlan J, Maylin S, Delaugerre C, Peytavin G, Girard P, Zoulim F, Lacombe K. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: Virological and clinical implications. Hepatology 2014;60:497-507. [DOI: 10.1002/hep.27182] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 6.4] [Reference Citation Analysis]
91 Tang YZ, Liu L, Pan MM, Wang YM, Deng GH. Evolutionary pattern of full hepatitis B virus genome during sequential nucleos(t)ide analog therapy. Antiviral Res. 2011;90:116-125. [PMID: 21440005 DOI: 10.1016/j.antiviral.2011.03.183] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
92 Lee KS, Kim DJ; Guideline Committee of the Korean Association for the Study of the Liver. Management of Chronic Hepatitis B. Korean J Hepatol 2007;13:447. [DOI: 10.3350/kjhep.2007.13.4.447] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
93 Zoulim F, Lucifora J. Hepatitis B virus drug resistance: mechanism and clinical implications for the prevention of treatment failure. Future Virology 2006;1:361-76. [DOI: 10.2217/17460794.1.3.361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
94 Reijnders JG, Leemans WF, Hansen BE, Pas SD, de Man RA, Schutten M, Janssen HL. On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. J Viral Hepat 2009;16:113-20. [PMID: 19175883 DOI: 10.1111/j.1365-2893.2008.01053.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
95 Jacquard AC, Brunelle MN, Pichoud C, Durantel D, Carrouée-Durantel S, Trepo C, Zoulim F. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2’,3’-dideoxy-3’-fluoroguanosine. Antimicrob Agents Chemother. 2006;50:955-961. [PMID: 16495257 DOI: 10.1128/aac.50.3.955-961.2006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
96 Ohrui H, Kohgo S, Hayakawa H, Kodama E, Matsuoka M, Nakata T, Mitsuya H. 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of HIV-1 strains, favorable toxic profiles, and stability in plasma. Nucleosides Nucleotides Nucleic Acids 2007;26:1543-6. [PMID: 18066823 DOI: 10.1080/15257770701545218] [Cited by in F6Publishing: 32] [Reference Citation Analysis]
97 Cho SW, Koh KH, Cheong JY, Lee MH, Hong SP, Yoo WD, Kim S. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance. Journal of Viral Hepatitis 2010;17:171-7. [DOI: 10.1111/j.1365-2893.2009.01161.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
98 Liu LJ, Wang JH, Du SC, Tian JH, Yang RF, Wei L. rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B. J Viral Hepat. 2010;17 Suppl 1:66-72. [PMID: 20586936 DOI: 10.1111/j.1365-2893.2010.01273.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
99 Durantel D, Carrou�e-durantel S, Werle-lapostolle B, Brunelle M, Pichoud C, Tr�po C, Zoulim F. A new strategy for studyingin vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology 2004;40:855-64. [DOI: 10.1002/hep.20388] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 4.3] [Reference Citation Analysis]
100 Suzuki F, Kumada H, Nakamura H. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy. J Med Virol 2006;78:1025-34. [DOI: 10.1002/jmv.20658] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
101 Nassal M, Dallmeier K, Schultz U, Sun D. Phenotyping hepatitis B virus variants: from transfection towards a small animal in vivo infection model. J Clin Virol. 2005;34 Suppl 1:S89-S95. [PMID: 16461231 DOI: 10.1016/S1386-6532(05)80017-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
102 Hu JL, Cui J, Guo JJ, Zhang WL, Cai XF, Yuan ZW, Li QL, Deng XY, Zeng AZ, Hu Y, Tang N, Huang AL. Phenotypic assay of a hepatitis B virus strain carrying an rtS246T variant using a new strategy. J Med Virol 2012;84:34-43. [PMID: 22052677 DOI: 10.1002/jmv.22260] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
103 Khamduang W, Ngo-Giang-Huong N, Gaudy-Graffin C, Jourdain G, Suwankornsakul W, Jarupanich T, Chalermpolprapa V, Nanta S, Puarattana-Aroonkorn N, Tonmat S. Prevalence, risk factors, and impact of isolated antibody to hepatitis B core antigen and occult hepatitis B virus infection in HIV-1-infected pregnant women. Clin Infect Dis. 2013;56:1704-1712. [PMID: 23487379 DOI: 10.1093/cid/cit166] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
104 Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006;44:1656-65. [DOI: 10.1002/hep.21422] [Cited by in Crossref: 270] [Cited by in F6Publishing: 239] [Article Influence: 16.9] [Reference Citation Analysis]
105 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 19.2] [Reference Citation Analysis]
106 Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am. 2010;24:809-833. [PMID: 20674805 DOI: 10.1016/j.idc.2010.07.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
107 Stray SJ, Bourne CR, Punna S, Lewis WG, Finn MG, Zlotnick A. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci U S A 2005;102:8138-43. [PMID: 15928089 DOI: 10.1073/pnas.0409732102] [Cited by in Crossref: 178] [Cited by in F6Publishing: 169] [Article Influence: 10.5] [Reference Citation Analysis]
108 Deterding K, Manns MP, Wedemeyer H. Does the presence of adefovir-resistant variants lead to failure of tenofovir monotherapy? J Hepatol 2008;49:862-3. [PMID: 18804309 DOI: 10.1016/j.jhep.2008.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
109 Buti M, Castells L. Prevention and treatment of hepatitis B virus recurrence after liver transplantation: . Current Opinion in Organ Transplantation 2006;11:589-93. [DOI: 10.1097/mot.0b013e3280102b22] [Reference Citation Analysis]
110 Guo J, Li Q, Shi X, Zhang D, Zeng A, Feng T, Huang A. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient. Antiviral Research 2009;81:180-3. [DOI: 10.1016/j.antiviral.2008.09.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
111 Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol. 2008;48:391-398. [PMID: 18199519 DOI: 10.1016/j.jhep.2007.09.020] [Cited by in Crossref: 97] [Cited by in F6Publishing: 89] [Article Influence: 6.9] [Reference Citation Analysis]
112 Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507-539. [PMID: 17256718 DOI: 10.1002/hep.21513] [Cited by in Crossref: 1675] [Cited by in F6Publishing: 1543] [Article Influence: 111.7] [Reference Citation Analysis]
113 Khamduang W, Gaudy-Graffin C, Ngo-Giang-Huong N, Jourdain G, Moreau A, Borkird T, Layangool P, Kamonpakorn N, Jitphiankha W, Kwanchaipanich R, Potchalongsin S, Lallemant M, Sirirungsi W, Goudeau A; Program for HIV Prevention and Treatment (PHPT) group. Analysis of residual perinatal transmission of hepatitis B virus (HBV) and of genetic variants in human immunodeficiency virus and HBV co-infected women and their offspring. J Clin Virol 2013;58:415-21. [PMID: 23916828 DOI: 10.1016/j.jcv.2013.06.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
114 Bailly F, Zoulim F. [Treatment of hepatitis B. Therapeutic management]. Gastroenterol Clin Biol 2008;32:S172-8. [PMID: 18472238 DOI: 10.1016/j.gcb.2008.04.008] [Reference Citation Analysis]
115 Terrault NA. Benefits and risks of combination therapy for hepatitis B. Hepatology 2009;49:S122-8. [DOI: 10.1002/hep.22921] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
116 Thibault V, Gaudy-Graffin C, Colson P, Gozlan J, Schnepf N, Trimoulet P, Pallier C, Saune K, Branger M, Coste M, Thoraval FR; ANRS Multivir-HBV group. Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study. Virol J 2013;10:87. [PMID: 23497042 DOI: 10.1186/1743-422X-10-87] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
117 Zoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res. 2006;71:206-215. [PMID: 16716414 DOI: 10.1016/j.antiviral.2006.04.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
118 Maynard M, Parvaz P, Durantel S, Chevallier M, Chevallier P, Lot M, Trepo C, Zoulim F. Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. J Hepatol. 2005;42:279-281. [PMID: 15664258 DOI: 10.1016/j.jhep.2004.09.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
119 Reijnders JG, Pas SD, Schutten M, de Man RA, Janssen HL. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol. 2009;50:674-683. [PMID: 19231002 DOI: 10.1016/j.jhep.2008.10.033] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
120 Dusheiko G. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Liver Int. 2013;33 Suppl 1:137-150. [PMID: 23286858 DOI: 10.1111/liv.12078] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
121 Mutimer D. Adefovir-lamivudine combination therapy and hepatitis B viral kinetics. Journal of Hepatology 2005;43:200-2. [DOI: 10.1016/j.jhep.2005.05.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
122 Durantel D. Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied? Antivir Ther. 2010;15:521-527. [PMID: 20516574 DOI: 10.3851/imp1551] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
123 Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis. 2008;8:167-178. [PMID: 18053766 DOI: 10.1016/s1473-3099(07)70264-5] [Cited by in Crossref: 138] [Cited by in F6Publishing: 55] [Article Influence: 9.2] [Reference Citation Analysis]
124 Trautwein C. Mechanisms of hepatitis B virus graft reinfection and graft damage after liver transplantation. J Hepatol. 2004;41:362-369. [PMID: 15336437 DOI: 10.1016/j.jhep.2004.06.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
125 Menne S, Cote PJ, Korba BE, Butler SD, George AL, Tochkov IA, Delaney WE, Xiong S, Gerin JL, Tennant BC. Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother. 2005;49:2720-2728. [PMID: 15980342 DOI: 10.1128/aac.49.7.2720-2728.2005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
126 Roche B, Samuel D. [Liver transplantation for complications of hepatitis B]. Presse Med 2006;35:335-45. [PMID: 16493338 DOI: 10.1016/s0755-4982(06)74579-1] [Reference Citation Analysis]
127 Yatsuji H, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Iwao E, Fujimoto Y, Ochi H. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother. 2006;50:3867-3874. [PMID: 16982790 DOI: 10.1128/aac.00239-06] [Cited by in Crossref: 51] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
128 Herbers U, Amini-Bavil-Olyaee S, Mueller A, Luedde T, Trautwein C, Tacke F. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains. J Viral Hepat. 2013;20:141-148. [PMID: 23301549 DOI: 10.1111/j.1365-2893.2012.01639.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
129 Thermet A, Buronfosse T, Werle-Lapostolle B, Chevallier M, Pradat P, Trepo C, Zoulim F, Cova L. DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection. J Gen Virol. 2008;89:1192-1201. [PMID: 18420797 DOI: 10.1099/vir.0.83583-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
130 Papatheodoridis GV, Deutsch M. Resistance issues in treating chronic hepatitis B. Future Microbiology 2008;3:525-38. [DOI: 10.2217/17460913.3.5.525] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
131 Yang HJ, Lee JH, Kim YJ, Yoon JH, Lee HS. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance. J Med Virol. 2012;84:424-430. [PMID: 22246827 DOI: 10.1002/jmv.23229] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
132 Kotlyar DS, Campbell MS, Reddy KR. Recurrence of diseases following orthotopic liver transplantation. Am J Gastroenterol. 2006;101:1370-1378. [PMID: 16771963 DOI: 10.1111/j.1572-0241.2006.00586.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
133 Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology. 2009;50:1064-1071. [PMID: 19637288 DOI: 10.1002/hep.23145] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
134 Lim YS. Management of Antiviral Resistance in Chronic Hepatitis B. Gut Liver 2017;11:189-95. [PMID: 28183162 DOI: 10.5009/gnl15562] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
135 Schreibman IR, Schiff ER. Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Ann Clin Microbiol Antimicrob 2006;5:8. [PMID: 16600049 DOI: 10.1186/1476-0711-5-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
136 Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 2008; 14(45): 6902-6910 [PMID: 19058323 DOI: 10.3748/wjg.14.6902] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
137 Zeng M, Mao Y, Yao G, Wang H, Hou J, Wang Y, Ji BN, Chang CN, Barker KF. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006;44:108-16. [PMID: 16799983 DOI: 10.1002/hep.21225] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 3.3] [Reference Citation Analysis]
138 Komatsu H, Inui A, Suzuki Y, Sugiyama M, Fujisawa T. Deep sequencing of hepatitis B surface antigen gene in the preserved umbilical cords in immunoprophylaxis failure against mother-to-child HBV transmission. BMC Infect Dis 2019;19:985. [PMID: 31752732 DOI: 10.1186/s12879-019-4624-9] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
139 Zoulim F, Locarnini S. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int 2013;33:116-24. [DOI: 10.1111/liv.12069] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
140 De Clercq E, Férir G, Kaptein S, Neyts J. Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses 2010;2:1279-305. [PMID: 21994680 DOI: 10.3390/v2061279] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
141 Danta M, Dusheiko G. Adefovir dipivoxil: review of a novel acyclic nucleoside analogue. Int J Clin Pract. 2004;58:877-886. [PMID: 15529522 DOI: 10.1111/j.1742-1241.2004.00364.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
142 Sinn DH, Lee HI, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Virological response to adefovir monotherapy and the risk of adefovir resistance. World J Gastroenterol 2011; 17(30): 3526-3530 [PMID: 21941420 DOI: 10.3748/wjg.v17.i30.3526] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
143 Ducancelle A, Abgueguen P, Birguel J, Mansour W, Pivert A, Le Guillou-Guillemette H, Sobnangou JJ, Rameau A, Huraux JM, Lunel-Fabiani F. High endemicity and low molecular diversity of hepatitis B virus infections in pregnant women in a rural district of North Cameroon. PLoS One 2013;8:e80346. [PMID: 24265811 DOI: 10.1371/journal.pone.0080346] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
144 Wang Y, Liu S, Chen Y, Zheng S, Zhou L, Lu F, Duan Z. Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy. Int J Med Sci 2015;12:416-22. [PMID: 26005376 DOI: 10.7150/ijms.11687] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
145 Hynicka LM, Yunker N, Patel PH. A Review of Oral Antiretroviral Therapy for the Treatment of Chronic Hepatitis B. Ann Pharmacother 2010;44:1271-86. [DOI: 10.1345/aph.1m590] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
146 Sheldon J, Sarmento E Castro R, Soriano V. [Resistance in hepatitis B virus]. Enferm Infecc Microbiol Clin 2008;26 Suppl 7:49-55. [PMID: 19100231 DOI: 10.1016/s0213-005x(08)76519-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
147 Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology. 2005;42:1414-1419. [PMID: 16317671 DOI: 10.1002/hep.20939] [Cited by in Crossref: 202] [Cited by in F6Publishing: 184] [Article Influence: 11.9] [Reference Citation Analysis]
148 Jung YK, Yeon JE, Han WS, Kim JH, Kim JH, Park JJ, Kim JS, Bak YT, Yoo W, Hong SP, Kim SO, Kwon SY, Byun KS, Lee CH. Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated Lamivudine-resistant chronic hepatitis B. Gut Liver 2010;4:212-8. [PMID: 20559524 DOI: 10.5009/gnl.2010.4.2.212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
149 Michalak TI, Zhang H, Churchill ND, Larsson T, Johansson NG, Oberg B. Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B. Antimicrob Agents Chemother. 2009;53:3803-3814. [PMID: 19564357 DOI: 10.1128/aac.00263-09] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
150 Fan XH, Geng JZ, Wang LF, Zheng YY, Lu HY, Li J, Xu XY. De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients. World J Gastroenterol 2011; 17(43): 4804-4809 [PMID: 22147982 DOI: 10.3748/wjg.v17.i43.4804] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
151 Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol. 2006;44:593-606. [PMID: 16455151 DOI: 10.1016/j.jhep.2006.01.001] [Cited by in Crossref: 148] [Cited by in F6Publishing: 143] [Article Influence: 9.3] [Reference Citation Analysis]
152 Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trépo C, Zoulim F. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol. 2007;46:531-538. [PMID: 17239478 DOI: 10.1016/j.jhep.2006.11.016] [Cited by in Crossref: 117] [Cited by in F6Publishing: 114] [Article Influence: 7.3] [Reference Citation Analysis]
153 Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 2004;48:3498-3507. [PMID: 15328117 DOI: 10.1128/aac.48.9.3498-3507.2004] [Cited by in Crossref: 407] [Cited by in F6Publishing: 120] [Article Influence: 22.6] [Reference Citation Analysis]
154 Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, Seo YS, Chung HJ, Moon MS, Kim SO. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut. 2006;55:1488-1495. [PMID: 16461777 DOI: 10.1136/gut.2005.077099] [Cited by in Crossref: 158] [Cited by in F6Publishing: 144] [Article Influence: 9.9] [Reference Citation Analysis]
155 Kim SS, Cheong JY, Cho SW. Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Gut Liver 2011;5:278-87. [PMID: 21927654 DOI: 10.5009/gnl.2011.5.3.278] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
156 Zoulim F. Entecavir: a new treatment option for chronic hepatitis B. J Clin Virol. 2006;36:8-12. [PMID: 16515882 DOI: 10.1016/j.jcv.2006.01.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
157 Bárcena R, Del Campo S, Moraleda G, Casanovas T, Prieto M, Buti M, Moreno J, Cuervas V, Fraga E, De la Mata M, Otero A, Delgado M, Loinaz C, Barrios C, Dieguez M, Mas A, Sousa J, Herrero J, Muñoz R, Avilés J, Gonzalez A, Rueda M. Study on the Efficacy and Safety of Adefovir Dipivoxil Treatment in Post–Liver Transplant Patients With Hepatitis B Virus Infection and Lamivudine-Resistant Hepatitis B Virus. Transplantation Proceedings 2005;37:3960-2. [DOI: 10.1016/j.transproceed.2005.10.061] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
158 Tan TMC, Chen Y, Kong KH, Bai J, Li Y, Lim SG, Ang TH, Lam Y. Synthesis and the biological evaluation of 2-benzenesulfonylalkyl-5-substituted-sulfanyl-[1,3,4]-oxadiazoles as potential anti-hepatitis B virus agents. Antiviral Research 2006;71:7-14. [DOI: 10.1016/j.antiviral.2006.02.007] [Cited by in Crossref: 101] [Cited by in F6Publishing: 67] [Article Influence: 6.3] [Reference Citation Analysis]
159 Lok AS. Evolution of nucleoside/tide analogues for hepatitis B: is the ideal drug here yet? J Hepatol 2009;51:416-8. [PMID: 19410323 DOI: 10.1016/j.jhep.2009.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
160 Eisenbach C, Sauer P, Mehrabi A, Stremmel W, Encke J. Prevention of hepatitis B virus recurrence after liver transplantation. Clin Transplant 2006;20 Suppl 17:111-6. [PMID: 17100710 DOI: 10.1111/j.1399-0012.2006.00609.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
161 Zoulim F, Durantel D, Deny P. Management and prevention of drug resistance in chronic hepatitis B. Liver Int. 2009;29 Suppl 1:108-115. [PMID: 19207973 DOI: 10.1111/j.1478-3231.2008.01939.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
162 Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:1593-1608.e1-e2. [PMID: 19737565 DOI: 10.1053/j.gastro.2009.08.063] [Cited by in Crossref: 468] [Cited by in F6Publishing: 443] [Article Influence: 36.0] [Reference Citation Analysis]
163 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]
164 Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology. 2009;49:S174-S184. [PMID: 19399794 DOI: 10.1002/hep.22900] [Cited by in Crossref: 142] [Cited by in F6Publishing: 140] [Article Influence: 10.9] [Reference Citation Analysis]
165 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 21.3] [Reference Citation Analysis]
166 Vierling JM. Management of HBV Infection in Liver Transplantation Patients. Int J Med Sci 2005;2:41-9. [PMID: 15968339 DOI: 10.7150/ijms.2.41] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
167 Stephan C, Berger A, Carlebach A, Lutz T, Bickel M, Klauke S, Staszewski S, Stuermer M. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. Journal of Antimicrobial Chemotherapy 2005;56:1087-93. [DOI: 10.1093/jac/dki396] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
168 Ohrui H. 2′-deoxy′4′-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity. Chem Record 2006;6:133-43. [DOI: 10.1002/tcr.20078] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
169 Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution. Virus Res. 2007;127:164-176. [PMID: 17383765 DOI: 10.1016/j.virusres.2007.02.021] [Cited by in Crossref: 173] [Cited by in F6Publishing: 175] [Article Influence: 11.5] [Reference Citation Analysis]
170 Jacquard AC, Nassal M, Pichoud C, Ren S, Schultz U, Guerret S, Chevallier M, Werle B, Peyrol S, Jamard C, Rimsky LT, Trepo C, Zoulim F. Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother. 2004;48:2683-2692. [PMID: 15215126 DOI: 10.1128/aac.48.7.2683-2692.2004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
171 Raimondo G, Cacciamo G, Saitta C. Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease? Annals of Hepatology 2005;4:100-6. [DOI: 10.1016/s1665-2681(19)32072-1] [Cited by in Crossref: 23] [Article Influence: 1.4] [Reference Citation Analysis]
172 Moses SE, Lim ZY, Sudhanva M, Devereux S, Ho AY, Pagliuca A, Zuckerman M, Mufti GJ. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. J Med Virol. 2006;78:1560-1563. [PMID: 17063522 DOI: 10.1002/jmv.20705] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
173 Echevarría-Mayo JM. [Etiology and pathogenesis of viral hepatitis]. Enferm Infecc Microbiol Clin 2006;24:45-56. [PMID: 16537063 DOI: 10.1157/13083375] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
174 Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007; 13(1): 125-140 [PMID: 17206760 DOI: 10.3748/wjg.v13.i1.125] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]
175 Srivastav NC, Shakya N, Mak M, Agrawal B, Tyrrell DL, Kumar R. Antiviral Activity of Various 1-(2′-Deoxy-β- d -lyxofuranosyl), 1-(2′-Fluoro-β- d -xylofuranosyl), 1-(3′-Fluoro-β- d -arabinofuranosyl), and 2′-Fluoro-2′,3′-didehydro-2′,3′-dideoxyribose Pyrimidine Nucleoside Analogues against Duck Hepatitis B Virus (DHBV) and Human Hepatitis B Virus (HBV) Replication. J Med Chem 2010;53:7156-66. [DOI: 10.1021/jm100803c] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
176 Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 2006;44:703-712. [PMID: 16941700 DOI: 10.1002/hep.21290] [Cited by in Crossref: 190] [Cited by in F6Publishing: 180] [Article Influence: 11.9] [Reference Citation Analysis]
177 Zoulim F, Parvaz P, Marcellin P, Zarski J, Beaugrand M, Benhamou Y, Bailly F, Maynard M, Trepo C, Trylesinski A, Monchecourt F; the VIRESPA study group. Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. Liver International 2009;29:420-6. [DOI: 10.1111/j.1478-3231.2008.01867.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
178 Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trépo C, Zoulim F. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol. 2008;48:747-755. [PMID: 18331765 DOI: 10.1016/j.jhep.2008.01.027] [Cited by in Crossref: 143] [Cited by in F6Publishing: 141] [Article Influence: 10.2] [Reference Citation Analysis]
179 Min AD, Dienstag JL. Oral antivirals for chronic hepatitis B. Clin Liver Dis 2007;11:851-68, ix. [PMID: 17981232 DOI: 10.1016/j.cld.2007.08.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
180 Pawlotsky JM. The concept of hepatitis B virus mutant escape. J Clin Virol. 2005;34 Suppl 1:S125-S129. [PMID: 16461211 DOI: 10.1016/s1386-6532(05)80021-6] [Cited by in Crossref: 57] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
181 Jung J, Kim NK, Park S, Shin HJ, Hwang SG, Kim K. Inhibitory effect of Phyllanthus urinaria L. extract on the replication of lamivudine-resistant hepatitis B virus in vitro. BMC Complement Altern Med. 2015;15:255. [PMID: 26220282 DOI: 10.1186/s12906-015-0792-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
182 Asselah T, Lada O, Boyer N, Martinot M, Marcellin P. [Treatment of chronic hepatitis B]. Gastroenterol Clin Biol. 2008;32:749-768. [PMID: 18775613 DOI: 10.1016/j.gcb.2008.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
183 Arrese E, Basaras M, Blanco S, Ruiz P, Cisterna R. Monitoring of therapy in patients with chronic hepatitis B virus. Eur J Gastroenterol Hepatol 2010;22:736-40. [PMID: 19550344 DOI: 10.1097/MEG.0b013e32832e0a44] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
184 Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am 2010;24:413-37. [PMID: 20466277 DOI: 10.1016/j.idc.2010.01.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
185 Yuen MF, Fung J, Wong DK, Lai CL. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect Dis. 2009;9:256-264. [PMID: 19324298 DOI: 10.1016/s1473-3099(09)70056-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
186 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2005; 13(4): 543-545 [DOI: 10.11569/wcjd.v13.i4.543] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
187 Ahn SH, Chun JY, Shin SK, Park JY, Yoo W, Hong SP, Kim SO, Han KH. Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B. Clin Mol Hepatol 2013;19:399-408. [PMID: 24459645 DOI: 10.3350/cmh.2013.19.4.399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
188 Khamduang W, Gaudy-Graffin C, Ngo-Giang-Huong N, Jourdain G, Moreau A, Luekamlung N, Halue G, Buranawanitchakorn Y, Kunkongkapan S, Buranabanjasatean S, Lallemant M, Sirirungsi W, Goudeau A; Program for HIV Prevention and Treatment Study Group. Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand. PLoS One 2012;7:e42184. [PMID: 22860080 DOI: 10.1371/journal.pone.0042184] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
189 Lee YS, Chung YH, Kim JA, Jin YJ, Park WH, Kim SE, Lee D, Shim JH, Kim KM, Lim YS. rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy. J Gastroenterol Hepatol. 2012;27:300-305. [PMID: 21777282 DOI: 10.1111/j.1440-1746.2011.06853.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
190 Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, Hussain M, Lok AS. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 2006;44:283-290. [PMID: 16338024 DOI: 10.1016/j.jhep.2005.10.018] [Cited by in Crossref: 247] [Cited by in F6Publishing: 210] [Article Influence: 14.5] [Reference Citation Analysis]
191 Zoulim F, Radenne S, Ducerf C. Management of patients with decompensated hepatitis B virus associated cirrhosis. Liver Transpl 2008;14:S1-7. [DOI: 10.1002/lt.21615] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
192 Littler E, Zhou X. Deoxyribonucleic Acid Viruses: Antivirals for Herpesviruses and Hepatitis B Virus. Comprehensive Medicinal Chemistry II. Elsevier; 2007. pp. 295-327. [DOI: 10.1016/b0-08-045044-x/00212-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
193 Férir G, Kaptein S, Neyts J, De Clercq E. Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Rev Med Virol. 2008;18:19-34. [PMID: 17966115 DOI: 10.1002/rmv.554] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
194 Wei C, Chong YT, Wen JZ, Li YW, Li G. Characterization of hepatitis virus B isolated from a multi-drug refractory patient. Virus Res 2011;155:254-8. [PMID: 20970466 DOI: 10.1016/j.virusres.2010.10.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
195 Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, Fang J, Yu CF, Zhang S, Mazzucco CE, Eggers B, Hsu M, Plym MJ, Poundstone P, Yang J, Colonno RJ. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007;51:902-11. [PMID: 17178796 DOI: 10.1128/AAC.00833-06] [Cited by in Crossref: 172] [Cited by in F6Publishing: 50] [Article Influence: 10.8] [Reference Citation Analysis]
196 Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol. 2012;56 Suppl 1:S112-S122. [PMID: 22300461 DOI: 10.1016/s0168-8278(12)60012-9] [Cited by in Crossref: 90] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
197 Sheen E, Trinh HN, Nguyen TT, Do ST, Tran P, Nguyen HA, Nguyen KK, Garcia RT, Nguyen MH. The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir: Entecavir for adefovir partial responders. Alimentary Pharmacology & Therapeutics 2011;34:767-74. [DOI: 10.1111/j.1365-2036.2011.04785.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
198 Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouée-Durantel S, Villeneuve JP, Trépo C, Zoulim F. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology. 2005;41:1391-1398. [PMID: 15915463 DOI: 10.1002/hep.20723] [Cited by in Crossref: 201] [Cited by in F6Publishing: 185] [Article Influence: 11.8] [Reference Citation Analysis]
199 Yim HJ. [Hepatitis B virus genetic diversity and mutant]. Korean J Hepatol. 2008;14:446-464. [PMID: 19119240 DOI: 10.3350/kjhep.2008.14.4.446] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
200 Mihm U, Gärtner BC, Faust D, Hofmann WP, Sarrazin C, Zeuzem S, Herrmann E. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy. J Hepatol 2005;43:217-24. [PMID: 15964093 DOI: 10.1016/j.jhep.2005.02.037] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
201 Deng X, Li Q, Guo J. Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy. Virus Genes 2013;47:1-9. [DOI: 10.1007/s11262-013-0915-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
202 Fung SK, Andreone P, Han SH, Rajender Reddy K, Regev A, Keeffe EB, Hussain M, Cursaro C, Richtmyer P, Marrero JA, Lok AS. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. Journal of Hepatology 2005;43:937-43. [DOI: 10.1016/j.jhep.2005.05.037] [Cited by in Crossref: 143] [Cited by in F6Publishing: 130] [Article Influence: 8.4] [Reference Citation Analysis]
203 Wang F, Wang H, Shen H, Meng C, Weng X, Zhang W. Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues. Clin Ther. 2009;31:360-366. [PMID: 19302908 DOI: 10.1016/j.clinthera.2009.02.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
204 Sun Z, Zhou L, Zeng H, Chen Z, Zhu H. Multiplex locked nucleic acid probes for analysis of hepatitis B virus mutants using real-time PCR. Genomics. 2007;89:151-159. [PMID: 16935466 DOI: 10.1016/j.ygeno.2006.07.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
205 Lampertico P, Aghemo A, Viganò M, Colombo M. HBV and HCV therapy. Viruses 2009;1:484-509. [PMID: 21994557 DOI: 10.3390/v1030484] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
206 Hongthanakorn C, Lok AS. New pharmacologic therapies in chronic hepatitis B. Gastroenterol Clin North Am 2010;39:659-80. [PMID: 20951923 DOI: 10.1016/j.gtc.2010.08.012] [Reference Citation Analysis]
207 Pallier C, Rodriguez C, Brillet R, Nordmann P, Hézode C, Pawlotsky JM. Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology 2009;49:50-9. [PMID: 19065672 DOI: 10.1002/hep.22634] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
208 Inoue J, Ueno Y, Wakui Y, Niitsuma H, Fukushima K, Yamagiwa Y, Shiina M, Kondo Y, Kakazu E, Tamai K. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. J Viral Hepat. 2011;18:206-215. [PMID: 20367795 DOI: 10.1111/j.1365-2893.2010.01301.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
209 Baldick CJ, Eggers BJ, Fang J, Levine SM, Pokornowski KA, Rose RE, Yu CF, Tenney DJ, Colonno RJ. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol. 2008;48:895-902. [PMID: 18362040 DOI: 10.1016/j.jhep.2007.12.024] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
210 Núñez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis 2005;5:374-82. [PMID: 15919623 DOI: 10.1016/S1473-3099(05)70141-9] [Cited by in Crossref: 46] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
211 Lenci I, Milana M, Grassi G, Manzia TM, Gazia C, Tisone G, Angelico R, Baiocchi L. Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger? World J Gastroenterol 2020; 26(18): 2166-2176 [PMID: 32476783 DOI: 10.3748/wjg.v26.i18.2166] [Cited by in CrossRef: 2] [Article Influence: 1.0] [Reference Citation Analysis]
212 Gérolami R, Borentain P, Colson P, Norguet E, Gérolami A, Tamalet C. Efficacy of hepatitis B virus (HBV) vaccination in treating lamivudine-resistant HBV reactivation following hepatitis B surface antigen seroconversion. Liver Int 2007;27:1417-21. [PMID: 18036104 DOI: 10.1111/j.1478-3231.2007.01541.x] [Reference Citation Analysis]
213 Yan J, Xie W, Wang L, Wang JB, Feng X, Song SJ, Liu SA, Wei HS. Application of nest PCR-RFLP in the detection of adefovir dipivoxil resistance-associated mutation in hepatitis B virus. Shijie Huaren Xiaohua Zazhi 2006; 14(7): 714-717 [DOI: 10.11569/wcjd.v14.i7.714] [Reference Citation Analysis]